Ascendis Pharma A (ASND) Non Operating Income (2012 - 2025)

Ascendis Pharma A has disclosed Non Operating Income across 14 years of filings, most recently posting $213.7 million for Q4 2025.

• Non Operating Income for Q4 2025 came in at $213.7 million, up 142.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $370.6 million (up 104.27% YoY), and the FY2025 annual result was $213.7 million, up 142.83% from the prior year.
• Non Operating Income came in at $213.7 million for Q4 2025 at Ascendis Pharma A, up from $88.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $213.7 million in Q4 2025 to a low of $24.5 million in Q4 2021.
• The 5-year median for Non Operating Income is $40.1 million (2023), against an average of $79.0 million.
• Across the five-year window, Non Operating Income gained 17.47% in 2022 and surged 142.83% in 2025, its largest moves.
• Ascendis Pharma A's Non Operating Income stood at $24.5 million in 2021, then rose by 17.47% to $28.8 million in 2022, then jumped by 39.49% to $40.1 million in 2023, then soared by 119.19% to $88.0 million in 2024, then surged by 142.83% to $213.7 million in 2025.
• The last three Non Operating Income figures came in at $213.7 million (Q4 2025), $88.0 million (Q4 2024), and $40.1 million (Q4 2023), per Business Quant data.